TELO

TELOMIR PHARMACEUTICALS, INC.

TELO · CIK 0001971532 · Annual (10-K) · Last 2 years

Financial Trends

Revenue
20232024
Net Income−$17M
20232024
Operating CF−$5M
20232024
Free Cash Flow
20232024

Income Statement

MetricFY 2024FY 2023
Revenue
Cost of Revenue
Gross Profit
R&D Expense$0.0B$0.0B
SG&A Expense
Operating Income
Net Income$-0.0B$-0.0B
EPS (Basic)$0.56$-0.48
EPS (Diluted)$0.56$-0.45

Balance Sheet

MetricFY 2024FY 2023
Total Assets$0.0B$0.0B
Current Assets$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B
Total Liabilities$0.0B$0.0B
Current Liabilities$0.0B$0.0B
Stockholders' Equity$0.0B$0.0B

Cash Flow Statement

MetricFY 2024FY 2023
Operating Cash Flow$-0.0B$-0.0B
Investing Cash Flow
Capital Expenditures
Financing Cash Flow$0.0B$0.0B